Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Kyle LaHucik

Senior Reporter

Novo Nordisk continues to sling obesity drug partnerships. Its latest biotech of choice is Septerna, which will help the Danish pharma make oral small molecules …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Lack of detail in Trump's drug price plan raises more questions than answers

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Senior Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B